| Name | Title | Contact Details |
|---|
BioTechniques is a New York, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
SHYFT has been an integral part of the life sciences ecosystem for over 10 years and as the market undergoes a dramatic transformation to deliver more personalized and value-based medicine, the role of SHYFT has never been more important. We built the SHYFT Platform to help life science companies integrate clinical and commercial data and translate it into patient-centric intelligence and analytics for use across functional groups, shortening development cycles and commercialization activities while improving the probability of success. With a long history of success and deep client partnerships, we understand the market transformation and the actionable intelligence required for successful launch, growth and maintenance of new therapies. At SHYFT, we collaborate with our clients to ensure their success not only today, but in the future by providing flexible, agile solutions based on deep industry expertise. With an impressive customer retention rate, we`re committed to our client`s success and serve as a true partner in the transformation.
Bayer and CRISPR Therapeutics have entered into an agreement to create Casebia to discover, develop and commercialize new breakthrough therapeutics to cure blood disorders, blindness, and congenital heart disease. CRISPR Therapeutics will contribute its proprietary CRISPR-Cas9 gene-editing technology and intellectual property, while Bayer will make available its protein engineering expertise and relevant disease know-how. It is the first long-term strategic partnership of its kind to make a substantial investment in the development of target delivery systems in an effort to bring systemic in vivo CRISPR-Cas9 gene editing technology applications to patients.
What unites us at Rentschler Biopharma, is the passion for what we do. As a full-service CDMO we are your outsourcing partner for the bioprocess development, cGMP manufacturing and aseptic filling of biopharmaceuticals as well as for the elaboration of approval strategies for your products. Thanks to our many years of experience, the quality of our associated consulting activities, and our expertise in finding solutions, we are among the top suppliers in our field. Founded in 1927, Rentschler is a family owned and independent company. Our company structure guarantees rapid decision-making and efficient, smooth-running processes, and consequently keeping project timelines. Already in the early beginnings of biotechnology, Rentschler has built up a reputation with the development of different Interferon products (Fiblaferon, Polyferon). Nowadays, our attention is firmly focused on your products. For the success of your project we can refer to our experience in various molecules like antibodies, fusion proteins or enzymes. Thanks to our focus on innovations, we are always on the cutting edge of technologies.